RECRUITING

Avecure Flexible Microwave Ablation Probe For Lung Nodules

Talk to us

Conditions

Stage I - II Primary Lung CancerStage I Lung CancerStage II Lung CancerLung Cancer Stage ILung Cancer Stage IILung Cancer

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size. This research study involves microwave ablation (MWA)

Official Title

Feasibility and Efficacy of the AveCure Flexible Microwave Ablation Probe for Peripheral Lung Nodule

Quick Facts

Study Start:2022-06-01
Study Completion:2025-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05281237

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:22 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Subject with Stage I - II primary lung cancer (Solitary nodules up to 3 cm) as defined by previous pathology or ROSE.
  2. * Pathological proof of target nodule/tumor type and malignancy with specimen considered adequate per institutional laboratory standards
  3. * Target nodule/tumor which can be accessed via navigational bronchoscopy and confirmed location with cone beam CT scan intra-operatively
  4. * Resection/surgical candidate (lobectomy or greater)
  5. * Participants must be at least 22 years old and able to provide consent
  1. * Subjects in whom flexible bronchoscopy is contraindicated
  2. * Target nodule \< 1.0 cm
  3. * Prior radiation or neo adjuvant chemotherapy of the target nodule/tumor
  4. * Any comorbidity that the investigator feels would interfere with the safety of the subject or the evaluation of study objectives
  5. * Pacemaker, implantable cardioverter, or another electronic implantable device
  6. * Patient cannot tolerate bronchoscopy
  7. * Patients with coagulopathy
  8. * Patients in other therapeutic lung cancer studies
  9. * Subject is pregnant or breastfeeding
  10. * COVID-19 positive patient at the time of procedure.

Contacts and Locations

Study Contact

Jason Beattie, MD
CONTACT
(617) 632- 8252
jbeattie@bidmc.harvard.edu

Principal Investigator

Jason Beattie, MD
PRINCIPAL_INVESTIGATOR
Beth Israel Deaconess Medical Center

Study Locations (Sites)

Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115
United States

Collaborators and Investigators

Sponsor: Beth Israel Deaconess Medical Center

  • Jason Beattie, MD, PRINCIPAL_INVESTIGATOR, Beth Israel Deaconess Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-06-01
Study Completion Date2025-06-30

Study Record Updates

Study Start Date2022-06-01
Study Completion Date2025-06-30

Terms related to this study

Keywords Provided by Researchers

  • Stage I - II primary lung cancer
  • Stage I Lung Cancer
  • Stage II Lung Cancer
  • Lung Cancer Stage I
  • Lung Cancer Stage II
  • Lung Cancer

Additional Relevant MeSH Terms

  • Stage I - II Primary Lung Cancer
  • Stage I Lung Cancer
  • Stage II Lung Cancer
  • Lung Cancer Stage I
  • Lung Cancer Stage II
  • Lung Cancer